Disease

SeqLL Announces Publication of a New Single-Cell Epitranscriptomic Method Powered by SeqLL’s tSMS® Platform

Molecule, National Human Genome Research Institute, Nature, Gene expression, RNA transfection, PCR, AML, National, Risk, RNA, NHGRI, Security (finance), Massachusetts, Hospital, NASDAQ, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, DNA, Single molecule fluorescent sequencing, User experience, Independent school district, SQL, Method, Lung cancer, Bias, CEO, Form, Company, Adenosine, Disease, Cell, Technology, Aichi M6A, Research, NIH, Forward-looking statement, Intellectual property, Doctor of Philosophy, Time, Massachusetts General Hospital, GLOBE, 3D printing, Pharmaceutical industry, Fine chemical
Thursday, September 23, 2021 - 7:49pm

WOBURN, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a development-stage life sciences instrumentation and research services company engaged in the development of scientific assets and novel intellectual property across multiple “omics” fields, today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods. The method was developed in collaboration with the laboratory of Bradley E. Bernstein, MD, PhD through grant R01-HG009269 from the National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI).

Key Points: 
  • However, this platform provides multifaceted information in single cell resolution, which will be helpful for cancer diagnosis and assessing its causality.
  • Using this epitranscriptomic method to profile single cells, researchers will have the power to reveal insights into complex biological pathways beyond those that current methods allow.
  • SeqLLs exclusive True Single Molecule Sequencing (tSMS) technology enables direct sequencing of millions of individual molecules.
  • The tSMS platform offers maximum flexibility and avoids many of the challenges common for standard sequencing approaches.

TV And Broadway Actress Julie Halston To Receive Tony Award For Advocacy Work In Support Of Pulmonary Fibrosis Foundation

Off-Broadway, Idiopathic pulmonary fibrosis, Tony Awards, Reunion, Associated, National Health Council, Hope, American Theatre Wing, Charity Navigator, Tootsie, Interstitial lung disease, CBS, Inflammation, Associated Press, The Broadway League, Patient, Pulmonary fibrosis, Sex, ILD, Physician, Isabel, Caregiver, Board, CEO, PFF, Scar, Television, Awareness, Disease, Research, PF, Better Business Bureau, Incidence, Foundation, Organization, Julie Halston, BBB, Cystic Fibrosis Foundation, City, Stephanie Mills, American, Education, Lung, Disorder, Nightclub
Thursday, September 23, 2021 - 7:29pm

CHICAGO, Sept. 23, 2021 /PRNewswire/ -- Actress and comedienne, Julie Halston, a dynamic advocate for people living with pulmonary fibrosis, will receive the 2020 Isabelle Stevenson Tony Award on Sunday, Sept. 26, in recognition of her charitable work for the Pulmonary Fibrosis Foundation (PFF).

Key Points: 
  • CHICAGO, Sept. 23, 2021 /PRNewswire/ -- Actress and comedienne, Julie Halston, a dynamic advocate for people living with pulmonary fibrosis, will receive the 2020 Isabelle Stevenson Tony Award on Sunday, Sept. 26, in recognition of her charitable work for the Pulmonary Fibrosis Foundation (PFF).
  • We are so thrilled Julie is receiving the Isabelle Stevenson Tony Award and we are truly grateful for all that she has done for our community."
  • The gala began as a tribute to former Associated Press theater critic, Michael Kuchwara, who died from idiopathic pulmonary fibrosis in 2010.
  • The Pulmonary Fibrosis Foundation is the nation's leading education and advocacy organization for the more than 250,000 Americans impacted by pulmonary fibrosis (PF) and interstitial lung disease (ILD).

Telo Genomics Announces Full-Services Investor Relations Agreement with Adelaide Capital

Publication, Pre-consultation Agreement (Japan), Molecular biology, Artificial intelligence, Compliance, Exercise, Consultant, TSX Venture Exchange, Liquid biopsy, Patient, Multiple myeloma, Alzheimer's disease, TELO, Lists of diseases, Legislation, Company, Marie Cassidy, Lymphatic system, Genome, Disease, Genomics, 3D, Industry, Pharmaceutical industry
Tuesday, September 21, 2021 - 1:45pm

Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - September 21, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has entered into a consulting agreement (the "Consulting Agreement") with Adelaide Capital Markets Inc. ("Adelaide") to provide investor relations consulting services to the Company in compliance with the policies and guidelines of the TSX Venture Exchange (the "TSXV") and applicable legislation.
  • Adelaide will provide investor relations and consulting services to the Company, effective September 15, 2021.
  • Under the terms of the Consulting Agreement, Adelaide will receive C$8,000 per month from the Company for an initial period of 6 months (subject to extension by mutual agreement) until March 15, 2022.
  • Adelaide will, among other things, assist with investor introductions and communications, respond to investor and shareholder inquires, work with TELO to prepare corporate materials and press releases and coordinate non-deal roadshows, virtual campaigns, and conferences.

Alpha Cognition Announces Pricing of Public Offering

Neurodegeneration, Indian stock exchange, Alzheimer's disease, Issue, Dementia, Sale, TSX Venture Exchange, Cognition, Central nervous system, Growth hacking, Marketing, Agent, Offering, Company, ACOG, Disease, SEDAR, Donepezil, Rivastigmine, ALS, Safety, Amyotrophic lateral sclerosis, Traumatic brain injury, Memantine, GLOBE, Security (finance), Dietary supplement, Pharmaceutical industry
Thursday, September 23, 2021 - 3:18pm

VANCOUVER, British Columbia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Alpha Cognition Inc. (“Alpha” or the “Company”) (TSXV:ACOG), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that, in connection with its previously announced overnight marketed offering, a syndicate of agents led by Raymond James Ltd. and including iA Private Wealth Inc. (collectively, the "Agents"), have agreed to sell 8,350,000 units ("Units") of the Company at a price of $1.50 per Unit (the "Issue Price") for aggregate gross proceeds of approximately $12.5 million (the "Offering"). Each Unit will consist of one common share in the capital of Alpha (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at a price of $1.75 for a period of 24 months from the closing date of the Offering.

Key Points: 
  • Each Unit will consist of one common share in the capital of Alpha (a Common Share) and one common share purchase warrant (a Warrant).
  • The Offering is being conducted pursuant to the Companys Canadian base shelf prospectus dated August 25, 2021 (the Base Shelf Prospectus).
  • A prospectus supplement (the Prospectus Supplement) relating to the Offering will be filed in each of the provinces of Canada, except Quebec.
  • Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis (ALS).

Celldex Announces Upcoming Presentation of CDX-0159 Phase 1b Results in Inducible Urticaria at the 2021 European Academy of Dermatology and Venereology (EADV) 30th Congress

EDT, Goal, Therapy, Human, Annual report, Interim, Metabolic pathway, Inflammation, Risk, Congress, Journal of the European Academy of Dermatology and Venereology, Allergy, Hypersensitivity, Private Securities Litigation Reform Act, NASDAQ, Cancer, Patient, KIT, Form 10-K, Immune system, Consultant, Company, Knowledge, Hives, Disease, COVID-19, Judgement, B cell, Research, SD, Cell, Survival, Forward-looking statement, Intellectual property, Quality of life, CET, GLOBE, Pharmaceutical industry, Vaccine
Thursday, September 23, 2021 - 1:01pm

CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.

Key Points: 
  • CDX-0159 is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity.
  • KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions.
  • In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease.
  • Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.

Poxel Reports Financial Results for First Half 2021 and Provides a Corporate Update

Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, EUR, Goal, Type 2 diabetes, Trial, Senior, Program, POC, ILC, Scientific communication, Chronic kidney disease, Director, ALD, TIMES, Inflammation, Investor relations, JPY, Lists of diseases, Association, Public relations, Adult, NASH, CEO, European Association for the Study of the Liver, Disease, Drug development, Male, AMN, VLCFA, Conditional sentence, Fatty liver disease, United Nations Scientific Committee on the Effects of Atomic Radiation, Pharmacology, Plasma, Tablet, EASL, Exocrine gland, Corporate communication, USD, Achievement, FXR, Therapy, Degenerative disease, Adrenoleukodystrophy, R, Pharmacokinetics, Nervous system, Sumitomo Dainippon Pharma, Euronext, Annual, Patient, Metaves, Imeglimin, Biomarker, Board, AMPK, IPF, Efficacy, CKD, Pharmaceutical industry, Medical device, Management
Thursday, September 23, 2021 - 4:45pm

This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.

Key Points: 
  • This achievement has strengthened our near-term financial position and will continue to enhance our financial foundation with associated future royalties and sales-based payments, said Thomas Kuhn, CEO of Poxel.
  • Poxel is well-positioned to leverage its existing platforms to develop therapeutics in rare metabolic diseases, Mr. Kuhn concluded.
  • In July 2021, Poxel received a milestone payment of JPY 1.75 billion (approximately EUR 13.2 million, USD 15.8 million)1 from Sumitomo Dainippon Pharma.
  • Revenue for the first half of 2021 mostly reflects the JPY 1.75 billion (EUR 13.2 million) milestone payment from Sumitomo Dainippon Pharma which Poxel received in July 2021.

Ovarian CanceRx: New Innovative Clinical Research Effort Seeks to Accelerate the Development of New Treatments for Deadliest Gynecological Cancer

Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Oncology, Clinical trial, Partnership, Human, Research, Capitol Hill, Efficiency, MIT, Ovarian cancer, Patient, Coalition, Therapy, Cancer, Multimedia, Laboratory, OCRA, Ovarian Cancer Research Alliance, CEO, Woman, Disease, Finance, Drug development, Survival, Massachusetts Institute of Technology, Breast cancer, Industry, Pharmaceutical industry, Birth control
Thursday, September 23, 2021 - 4:30pm

Working in collaboration with key members of the research, clinical and patient advocacy communities, Ovarian CanceRx capitalizes on novel drug development to give ovarian cancer patients access to potentially beneficial treatments at a time when they need them most now!

Key Points: 
  • Working in collaboration with key members of the research, clinical and patient advocacy communities, Ovarian CanceRx capitalizes on novel drug development to give ovarian cancer patients access to potentially beneficial treatments at a time when they need them most now!
  • While there are numerous randomized control trials in ovarian cancer, there are still significant unmet clinical needs in this field.
  • A key stakeholder in the effort is Ovarian Cancer Research Alliance (OCRA), the worlds largest ovarian cancer charity.
  • Through GCARs Ovarian CanceRx partnership we are gratified to support an innovative clinical trial design that will improve treatment for women with ovarian cancer.

NORD Welcomes Aliza Fink, D.Sc. as Director of Research Programs

Research, NIH Intramural Research Program, NORD, Health, National Organization for Rare Disorders, FDA, Multimedia, Patient, Doctor of Science, Boston University School of Public Health, Degenerative disease, University, CEO, Orphan Drug Act of 1983, Program, Growth, Disease, Control, Center, Public health, Fink, Cystic fibrosis, Cystic Fibrosis Foundation, Registry, Pharmaceutical industry
Thursday, September 23, 2021 - 4:43pm

as the new Director of Research Programs.

Key Points: 
  • as the new Director of Research Programs.
  • "Research gives hope to rare disease patients and their families across the globe, and NORD is thrilled to have such a capable director to lead our research efforts," saidPeter L. Saltonstall, President and CEO of NORD.
  • In her role, Fink will lead the strategic development, growth, and implementation of NORD's research and scientific activities, ensuring that NORD drives innovation and advancement while supporting the rare community with evidence-informed programs.
  • Prior to joining NORD, Fink was most recently Senior Director of Real-World Research at Cystic Fibrosis Foundation and brings over 20 years of experience in research and epidemiology to leading NORD's research portfolio.

Vivante Health Announces Study Findings to Support the Clinical Validation of the GIMate

Clinical trial, PPA, JMIR, Diagnosis, Health, Duke University, FDA, MD, Irritable bowel syndrome, CEO, NPA, Disease, Paradox of tolerance, Lactose intolerance, History, Gimat, Medical device, Dietary supplement, Health insurance
Thursday, September 23, 2021 - 4:05pm

HOUSTON, Sept. 23, 2021 /PRNewswire/ -- Vivante Health , the leading digital solution for digestive health and disease, announced study findings to support the clinical validation of their novel handheld breath testing device, the GIMate.

Key Points: 
  • HOUSTON, Sept. 23, 2021 /PRNewswire/ -- Vivante Health , the leading digital solution for digestive health and disease, announced study findings to support the clinical validation of their novel handheld breath testing device, the GIMate.
  • "These findings support the clinical foundation of the GIMate and will help us launch a broad range of potential novel clinical applications to support our members with their digestive health," Vivante Health's CEO Bill Snyder shared.
  • Vivante Health is planning to apply the findings to help symptomatic individuals without a diagnosis as well as those with common diagnoses such as Irritable Bowel Syndrome.
  • Vivante Health is an innovative digital healthcare company reinventing the way chronic conditions are managed, gut first.

Urology Care Foundation Announces Recipient of the 2021 Rising Stars in Urology Research Award

AUA, Assistant, American Urological Association, National, Multimedia, Time-invariant system, Patient, University of California, Irvine Medical Center, Physician, Caregiver, Division, Paruresis, University, MPH, Disease, Risk, Health policy, Female, NIH, Organization, Foundation, The, Yale University, Doctor of Philosophy, Education, Dentistry, Pharmaceutical industry, Medicine
Thursday, September 23, 2021 - 3:00pm

BALTIMORE, Sept. 23, 2021 /PRNewswire/ -- The American Urological Association (AUA) and the Urology Care Foundationthe official foundation of the AUA announced today A. Lenore Ackerman, MD, PhD as the recipient of the 2021 Rising Stars in Urology Research Award.

Key Points: 
  • BALTIMORE, Sept. 23, 2021 /PRNewswire/ -- The American Urological Association (AUA) and the Urology Care Foundationthe official foundation of the AUA announced today A. Lenore Ackerman, MD, PhD as the recipient of the 2021 Rising Stars in Urology Research Award.
  • The Rising Stars in Urology Research Award program was established in 2005 to encourage recipients to contribute to urology as both surgical specialists and scientists investigating causes, prevention, treatment and cures that will improve patients' lives.
  • "For more than 15 years, the Urology Care Foundation has supported the careers of talented surgeon scientists allowing them to successfully transition to independent investigators and establish their research careers through the Rising Stars in Urology Research Award," said Steven Kaplan, MD, AUA Research Chair.
  • About the Urology Care Foundation:The Urology Care Foundation is the world's leading nonprofit urological health foundation, and the official foundation of the American Urological Association.